NCT05054543View on ClinicalTrials.gov

Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

PHASE3TerminatedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

November 17, 2021

Primary Completion Date

August 22, 2024

Study Completion Date

August 22, 2024

Conditions
Relapsed/Refractory AML
Interventions
DRUG

Uproleselan

A rationally designed E-selectin antagonist used to inhibit binding of cells to E-selectin

DRUG

Placebo

0.9% Sodium Chloride

Trial Locations (2)

300020

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin

Unknown

The First Affiliated Hospital of Zhejiang University, Hangzhou

Sponsors

Lead Sponsor

Apollomics Inc.
All Listed Sponsors
lead

Apollomics Inc.

INDUSTRY